MinorSystemic retinoid (vitamin A derivative)×Second-generation antihistamine with additional PAF antagonism
Updated · Methodology
Mechanism
Several cytochrome P450 enzymes metabolise isotretinoin, and none of them plays a predominant role. Isotretinoin and its metabolites do not significantly change the activity of these enzymes (isotretinoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In vitro, isotretinoin is metabolised mainly by CYP2C8, CYP2C9, CYP3A4 and CYP2B6 (Absorica label, US Food and Drug Administration, FDA). Rupatadine is almost completely metabolised, mainly by CYP3A4, and is itself a weak CYP3A4 inhibitor. The dose of sensitive CYP3A4 substrates such as simvastatin and lovastatin, and of CYP3A4 substrates with a narrow therapeutic index such as ciclosporin and tacrolimus, may therefore need adjustment (rupatadine SmPC, AEMPS). Isotretinoin is not among these drugs, and neither SmPC names the other drug in its interaction section (isotretinoin and rupatadine SmPCs, AEMPS).
Symptoms
The documents describe no symptoms linked to this combination. Isotretinoin dries the skin, lips and eyes and can raise liver enzymes, blood lipids and creatine phosphokinase (CPK), especially with vigorous physical activity. Some people taking it develop depression, anxiety and mood changes (isotretinoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The most frequent adverse effects of rupatadine are somnolence, headache, fatigue, asthenia, dry mouth and dizziness, and rare asymptomatic CPK increases were seen in clinical trials (rupatadine SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of isotretinoin and rupatadine need no change. No document names the pair, and isotretinoin is not among the drugs whose dose may need adjustment with rupatadine (isotretinoin and rupatadine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). During isotretinoin treatment, liver enzymes and blood lipids are checked before the start, after one month and then every three months (isotretinoin SmPC, AEMPS). Isotretinoin is contraindicated in hepatic impairment, and rupatadine is not recommended in such patients because there is no clinical experience (isotretinoin and rupatadine SmPCs, AEMPS). Both drugs can raise creatine phosphokinase (CPK): isotretinoin mostly with vigorous physical activity, sometimes leading to rhabdomyolysis, and rupatadine rarely and without symptoms. The documents give no special measures for the combination (isotretinoin and rupatadine SmPCs, AEMPS). Until a person knows how rupatadine affects them, they should take care when driving (rupatadine SmPC, AEMPS). If isotretinoin causes somnolence, dizziness or reduced night vision, the person should not drive (isotretinoin SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Rupafin 10 mg comprimidos (rupatadina) (2021)– Ficha técnica de Rupafin 10 mg comprimidos (rupatadina)
- FDA: Absorica (isotretinoin) prescribing information (2026)– FDA, DailyMed SPL setid 3ef0cff8-19c1-4441-b780-fca6c7ee1615, Sun Pharmaceutical Industries, revision 08/2026, sections 7, 8.3
- AEMPS: Ficha técnica: Isotretinoína 10 mg (Acnemin) (nº registro 82566), secciones 4.3, 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 82566, revisión 08/2026, secciones 4.3, 4.4 y 4.5